Individual approach in the treatment of prolactinoma in a patient with multiple endocrine neoplasia type 1 syndrome

E. N. Kravchuk; U. A. Tsoy; S. V. Sereda; E. N. Grineva

doi:10.18705/2782-3806-2022-2-4-97-102

Individual approach in the treatment of prolactinoma in a patient with multiple endocrine neoplasia type 1 syndrome

E. N. Kravchuk, U. A. Tsoy, S. V. Sereda, E. N. Grineva

https://doi.org/10.18705/2782-3806-2022-2-4-97-102

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Prolactinoma and associated hyperprolactinemia is one of the main causes of infertility. The disease can develop within the framework of multiple endocrine neoplasia type 1 (MEN 1), and the management of such patients may differ from the treatment of sporadic forms. The article presents a clinical case of a patient with prolactinoma that developed as part of MEN1 syndrome who planned pregnancy. An individual approach to the choice of therapeutic tactics was demonstrated, which allowed solving the problem of restoring fertility.

Keywords

cabergoline, hyperprolactinaemia, MEN1, neurosurgery, pregnancy, prolactinoma

References

1. Maiter D, Primeau V. 2012 update in the treatment of prolactinomas. Ann Endocrinol. 2012;73:90-8.

2. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:273-88.

3. Molitch ME. Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205-13.

4. Melnichenko GA, Dzeranova LK, Pigarova EA, Vorotnikova SIu, Rozhinskaia LIa, Dedov II. Problemy Endokrinologii. 2013;59(6):19-26. In Russian

5. Akkus G, Karagun B, Yaldız HN, et al. Outcomes of surgical and/or medical treatment in patients with prolactinomas during long-term follow-up: a retrospective single-centre study. Horm Mol Biol Clin Investig. 2020;17;42(2):153-157.

6. Giusti F, Cianferotti L, Boaretto F, et al. Multiple endocrine neoplasia syndrome type 1: institution, management, and data analysis of a nationwide multicenter patient database. Endocrine. 2017;58(2):349-359.

7. Brandi ML, Agarwal SK, Perrier ND, et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev. 2021;42(2):133-170.

8. Dreijerink KM, Goudet P, Burgess JR, et al. Breast-cancer predisposition in multiple endocrine neoplasia type 1. N Engl J Med. 2014;371(6):583-584.

9. Tepede AA, Welch J, Lee M, et al. 18F-FDOPA PET/CT accurately identifies MEN1-associated pheochromocytoma. Endocrinol Diab Metab. 2020;2020:19-0156.

10. Trouillas J, Labat-Moleur F, Sturm N, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol. 2008;32(4):534-43.

11. Valea A, Sandru F, Petca A, et al. Aggressive prolactinoma. Exp Ther Med. 2022;23(1):74.

12. Goudet P, Murat A, Binquet C, et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg. 2010;34(2):249-255.

13. Goudet P, Dalac A, Le Bras M, et al. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d’étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568-1577.

14. Vannucci L, Marini F, Giusti F, et al. MEN1 in children and adolescents: Data from patients of a regional referral center for hereditary endocrine tumors. Endocrine. 2018 Feb;59(2):438-448.

15. Daglar HK, Kirbas A, Biberoglu E, et al. Management of a multiple endocrine neoplasia type 1 during pregnancy: a case report and review of the literature. J Exp Ther Oncol. 2016;11(3):217-220.

16. Mistry M, Gupta M, Kaler M. Pregnancy in multiple endocrine neoplasia type 1 equals multiple complications. Obstet Med. 2014;7(3):123-125.

17. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990- 3011.

18. Stratakis CA, Tichomirowa MA, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet. 2010;78(5):457-463.

19. Salenave S, Ancelle D, Bahougne T, et al. Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients. J Clin Endocrinol Metab. 2015;100(3):1177- 1186.

20. Park K, Park KH, Park HR, et al. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. J Korean Med Sci. 2021;36(15):e97.

21. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, et al. Surgery as a Viable Alternative FirstLine Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020;105(3):e32-41.

22. Maiter D. Prolactinoma and pregnancy: From the wish of conception to lactation. Ann Endocrinol (Paris). 2016;77(2):128-34.

For citations:

Kravchuk E.N., Tsoy U.A., Sereda S.V., Grineva E.N. Individual approach in the treatment of prolactinoma in a patient with multiple endocrine neoplasia type 1 syndrome. Russian Journal for Personalized Medicine. 2022;2(4):97-102. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-4-97-102

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2782-3806 (Print)
ISSN 2782-3814 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Russian Journal for Personalized Medicine

Individual approach in the treatment of prolactinoma in a patient with multiple endocrine neoplasia type 1 syndrome

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy